natgillin/translations-raw huggingface dataset:
A chimeric molecule comprising a ligand which specifically hinds to an antigen or receptor on a cell surface, conjugated or fused to 
(a) citokin, antitijelo ili fragment antitijela, koji se citokin, antitijelo ili fragment antitijela specifično veže na neki antigen ili receptor na površini stanice, konjugiran ili fuzioniran sa:
a hydrophilic binder; and 
hidrofilno vezivno sredstvo
The method of claim 10, wherein the dosage of LABA is eliminated at the end of the initial treatment period. The method of claim 10, wherein the dosage of LABA and/or ICS is gradually reduced or eliminated over the course of 2 to 8 weeks. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 12 ili 13, naznačen time što se doziranje LABA eliminira na kraju početnog razdoblja liječenja, i/ili pri čemu se doziranje LABA i/ili ICS postupno smanjuje ili eliminira tijekom vremena od 2 do 8 tjedana.
The subject of the utility model is a multi-purpose sports apparatus particularly for improving footballers' technical skills, comprising a foundation body (10) containing a playing surface (11) and an obstacle element (20). 
igraću površinu (11) osnovnog tijela (10) koja, gledano iz unutrašnjosti osnovnog tijela (10), ima u najmanju ruku djelomično udubljenu gornju površinu (15), -
An antibody or antigen-binding fragment thereof that specifically binds human interleukin-4 receptor (hIL-4R) for use in a method of treating a disease or disorder, wherein the disease or disorder is improved, ameliorated or inhibited by removal, inhibition or reduction of human interleukin-4 (hIL-4) activity, wherein the antibody or fragment thereof comprises a heavy chain variable region (HCVR) comprising the amino acid sequence shown in SEQ ID NO:162 and a light chain variable region (LCVR) comprising the amino acid sequence shown in SEQ ID NO:164. 
Antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično vezuje za humani interleukin-4 receptor (hIL-4R) (SEQ ID NO:274) za primjenu u metodi liječenja oboljenja ili poremećaja, naznačena time, što je oboljenje 1li poremećaj odabran iz skupine koja se sastoji od oboljenja pluća, upalnih poremećaja 1 alergijskih reakcija, pri čemu antitijelo ili njegov fragment sadrži varijabilnu regiju teškog lanca (HCVR) koja sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NOQO:162 i varijabilnu regiju lakog lanca (LCVR) koja sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO:164.
Optionally one brewing chamber and the steam outlet can be supplied with hot water from the thermoblocks. 
Izborno se iz termoblokova vruću vođu može dovoditi u jednu komora za kuhanje i na izlaz za vodenu paru.
Concentrated H2SO4 (0.5 mL) is carefully added and the reaction mixture is refluxed at 80°C for 1 hour. 
Oprezno se doda koncentriranu HoSO» (0,5 ml) i reakcijsku smjesu se refluktira 1 sat pri 80"C.
A carbonate salt of a cross-linked polymer made according to the process of claims 1-10 for removing phosphate from a subject and/or treating metabolic acidosis. 
Karbonatna sol umreženog polimera dobivena prema postupku prema zahtjevima 1-10 naznačena time da je za uklanjanje fosfata iz subjekta ifili liječenje metaboličke acidoze.
optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation. 
opcionalno, upute za (i) uporabu otopine ili (ii) rekonstituciju i/ili uporabu liofilizirane formulacije.
A pharmaceutical composition comprising an effective amount of the compound of claim 11, or the pharmaceutically acceptable salt thereof, and a pharmaceutical excipient. 
Farmaceutska smjesa, naznačena time, što sadrži farmaceutski ekscipijent i protiv virusa efikasnu količinu spoja iz bilo kojeg od zahtjeva 1 do 3.
From this spout 220, the beverage falls freely and directly into the single-dose vessel (cup or similar vessel) that is placed therebelow to collect the beverage for drinking. 
Iz tog mlaza 220 napitak slobodno pada izravno u posudu za jednu dozu (šalicu ili sličnu posudu), koju se stavi ispod, za prikupljanje napitka za pijenje.
The compound according to [11] or a pharmacologically acceptable salt thereof, wherein in the formula (I), Ar2 is a group selected from the group consisting of A1b), A2b), and A7c): 
Spoj u skladu sa patentnim zahtjevom 11 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje u formuli (1), Ar" je grupa odabrana iz grupe koja se sastoji od A1b), A2b), i A7c):
The buttress element 5 comprises a base 14, substantially flat, and slidable in use on the upper surface 10 of the sole, in the area of the first seat 9 and the cavity 13; the base 14 has in top plan view a profile which partially corresponds to that of the sole 2 in the area of the heel 4. 
Potporni element 5 ima uglavnom ravnu osnovicu 14, koja pri upotrebi može kliznuti na gornju površinu 10 potplata, u području prvog dosjeda 9 i gnijezda 13, a gledana odozgo osnovica 14 ima profil koji djelomično odgovara profilu potplata 2 u području pete 4.
The conjugate of claim 4, wherein the payload comprises a carbohydrate. 
Konjugat iz patentnog zahtjeva 4, gdje dio od značaja sadrži ugljikohidrat.
a positively or negatively charged polypeptide domain that spontaneously assumes a helical conformation linked to the fifth domain, wherein the positively charged polypeptide domain is an E-coil separator having the amino acid sequence of SEQ ID NO: 299 and the negatively charged polypeptide domain is a K-coil separator having the amino acid sequence of SEQ ID NO: 300, wherein when the first polypeptide chain comprises the E-coil separator, the second polypeptide chain comprises the K-coil separator, or when the first polypeptide chain comprises the K-coil separator, the second polypeptide chain comprises the E-coil separator; 
pozitivno ili negativno nabijenu polipeptidnu domenu koji spontano poprima spiralnu konformaciju vezana za petu domenu, pri čemu pozitivno nabijena polipeptidna domena je separator E-uzvojnice koji ima sekvencu aminokiseline od SEQ ID NO: 299 i negativno nabijena polipeptidna domena je separator K-uzvojnice koji ima sekvencu aminokiseline od SEQ ID NO: 300, pri čemu kada prvi polipeptidni lanac sadrži separator E-uzvojnice, drugi polipeptidni lanac sadrži separator K-uzvojnice, ili kada prvi polipeptidni lanac sadrži separator K-uzvojnice, drugi polipeptidni lanac sadrži separator E-uzvojnice;
it does not increase TSLP-stimulated secretion of TARC in cells expressing the TSLP-R. 
- ne povećava TSLP-stimulirano izlučivanje TARC u stanicama koje eksprimiraju TSLP-R.
According to one aspect of the present invention, said heterogeneous catalyst may have a BET surface area of at least 10 m2/g, such as 25 m2/g, and preferably at least 50 m2/g, such as 100 m2/g, and even more preferably at least 150 m2/g, such as at least 200 m2/g. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu navedeni heterogeni katalizator ima BET površinsko područje od najmanje 10 m"/g, kao što je 25 m"/g, poželjno najmanje 50 m/g, kao što je 100 m"/g, a još poželjnije najmanje 150 m/g, kao što je najmanje 200 m"/g.
The process of claim 11, comprising redirecting the water recovered from the engine exhaust for use in the step of adding water to the pre-fuel composition to cause evaporation of the dimethyl ether from the pre-fuel composition. 
Postupak sukladno patentnom zahtjevu 11, naznačen time da obuhvaća preusmjeravanje vode koja se dobiva iz ispušnih plinova motora za uporabu u koraku dodavanja vode u smjesu predgoriva kako bi dimetil eter ispario iz smjese predgoriva.
An isolated nucleic acid molecule comprising at least one of: 
Izolirana molekula nukleinske kiseline prema zahtjevu 6 naznačena time što se sastoji od:
a ligand which specifically binds to an antigen or receptor on the exterior of the cell, wherein the ligand is conjugated or fused to 
(a) citokin, antitijelo 1li fragment antitijela, koji se citokin, antitijelo ili fragment antitijela specifično vežu na neki antigen ili receptor vanjskog dijela spomenute stanice, konjugiran ili fuzioniran sa
Figure 2: release of formaldehyde due to prolonged immersion in water at 70°C, owing to a hydrolytic effect. 
Slika 2: Razvijanje formaldehida zbog dugotrajnog potapanja u vodu kod 70*C zbog hidroliticnog učinka.
A method for treating cancer in a subject, the method comprising: administering to said subject a pan-specific monoclonal antibody against Transforming Growth Factor beta (TGFB) in combination with a therapeutically effective amount of a capecitabine and ixabepilone. 
Farmaceutski pripravak za liječenje raka dojke kod subjekta, koji sadrži: terapijski učinkovitu količinu antagonista transformirajućeg faktora rasta beta (TGFß), kapecitabina, te iksabepilon, naznačen time da je navedeni antagonist TGFß prisutan u količini koja učinkovito pojačava učinkovitost kapecitabina i iksabepilona u liječenju navedenog raka dojke.
Leaching from preservative solution consisting of copper, ethanolamine and octanoic acid is comparable to leaching from copper-chromium treated wood (Table 1). TABLE 1 
Ispiranje iz otopine konzervansa koja se sastoji od bakra, etanolamina i oktanoične kiseline je usporedivo s ispiranjem iz drva tretiranog bakrom-kromom (Tablica 1).
X represents a carboxylic acid or a carboxamide selected from the group consisting of N-methyl carboxamide, N,N-dimethyl carboxamide, N-ethyl carboxamide and N,N-diethyl carboxamide; and Y is sulfoxide or sulfone. 
X predstavlja karboksilnu kiselinu ili karboksamid odabran iz skupine koju čine N-metil karboksamid, N,N-dimetil karboksamid, N-etil karboksamid i N,N-dietil karboksamid; 1 Y je sulfoksid ili sulfon.
A reactor according to any of the preceding claims, characterized in that it comprises sensor means of vibrations, such as accelerometers, for monitoring the frequency and amplitude of the oscillations of the oscillating mass and sensor means for controlling the physical parameters, such as temperature and pressure, in the restricted environments during the operation of the reactor. 
Reaktor u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži senzor vibracija, poput akcelerometara, za praćenje frekvencije 1 amplitude oscilacija oscilirajuće mase 1 senzor za upravljanje fizičkim parametrima, poput temperature i tlaka, u ograničenom okolišu tijekom rada reaktora.
In another embodiment, at least part of the introducer probe and at least part of the ablation probe can have complementary shapes preventing rotation of the ablation probe with respect to the introducer. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 
Sustav prema zahtjevu 1, naznačen time da barem dio uvodnika (102) i barem dio sonde za ablaciju (120) imaju komplementarne oblike koji sprječavaju rotaciju sonde za ablaciju u odnosu na uvodnik.
A compound of formula I in which 
1. Spoj formule I O
The composition of claim 1, wherein the chemical modification of the glycosaminoglycans, the hydrolysed glycosaminoglycans, the glycosamines of glycosaminoglycans or the blend of the different glycosaminoglycans, hydrolysed glycosaminoglycans, glycosamines of glycosaminoglycans is an esterification, or a deacetylation followed by an esterification and a carbamatation, or a deacetylation followed by a carbamatation with CC or PRE-CC. 
Sastav prema zahtjevu 1, 3 ili 4, u kojem kemijska modifikacija glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina iz glikozaminoglikana ili mješavine različitih glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina iz glikozaminoglikana je esterifikacija ili deacetilacija nakon koje slijedi esterifikacija i karbamatacija ili deacetilacija nakon koje slijedi karbamatacija s CC ili PRE-CC.
The mixture was cooled and diluted with ethyl acetate. 
Smjesa se hladi i razrijedi etil-acetatom.
contacting the antigen presenting cell of step (iii) with a T cell to evaluate the ability of the peptide to stimulate the T cell; and 
stavljanja u kontakt predočnih stanica iz koraka (iii) s T-stanicom kako bi se procijenilo sposobnost peptida da stimulira T-stanice; i
The method of claim 9, wherein the plurality of passengers comprises ten passengers. 
Metoda iz zahtjeva 9, naznačeno time da pluralitet putnika (108) sačinjava barem četrdeset putnika.
Process according any of the preceding claims wherein the formylating agent in step 4 is selected from the group consisting of DMF, 1-formyl-piperidine, 1-formyl piperazine, N-methyl-N-(2-pyridyl) formamide, N-methyl formanilide, Weinreb formamide. 
Postupak u skladu s bilo kojim navedenim zahtjevom naznačen time da se formilirajući agens u koraku 4 odabere iz skupine koja se sastoji do DMF, 1-formil-piperidina, 1-formil-piperazina, N-metil-N-(2-piridil)-formamida, N-metil-formanilida, Weinrebovog formamida.
3% (worsened) dystrophy 
3% (pogoršanje) Distrofija
A glycosylated human Serum Amyloid P (SAP) polypeptide for use in inhibiting fibrocyte differentiation, wherein the SAP polypeptide comprises an N-linked oligosaccharide chain, and wherein at least one branch of the oligosaccharide chain terminates with a a2,3-linked sialic acid moiety. 
Glikozilirani humani serumski amiloidni P (SAP) polipeptid za upotrebu u inhibiranju diferencijacije monocita u fibrocite, naznačen time, da SAP polipeptid sadržava N-vezani oligosaharidni lanac 1 pri čemu barem jedna grana oligosaharidnog lanca završava s 02,3- vezanim ostatkom sijalične kiseline.
To a solution of intermediate 27 obtained above in absolute ethanol (50 mL) and anhydrous tetrahydrofuran (75 mL) was added anhydrous potassium carbonate (3.46 g, 25 mmol), and the reaction was stirred with heating (65° C.) for 20 hrs. 
U otopinu Intermedijera 27 dobivenog prema prethodnom tekstu u apsolutnom etanolu (50 mL) i bezvodnog tetrahidrofurana (75 mL) dodan je bezvodni kalij karbonat (3.46 g, 25 mmol), i reakcija je miješana uz zagrijavanje (65*C) 20 sati.
adjusting the solution resulting from step (iii) to a protein concentration of 5 to 7% and a pH value of 5.5 to 7; and 
(iv) podešavanje otopine dobivene u koraku (iii) do koncentracije proteina od 5 do 7% i pH vrijednosti od 5.5 do
A compound according to claim 12, wherein R5 is selected from methyl, isopropyl and tert-butyl. 
Spoj prema patentnom zahtjevu 11, naznačen time što je R5 izabran od metila, izopropila i terc-butila.
subsequently passing through the filtration material a basic flow at pH >10 and recirculating it through said material for a time sufficient to saturate it with arsenic, 
naknadno se kroz materijal za filtriranje propušta bazični tok s pH >10, te recirkulira kroz navedeni materijal kroz vrijeme dovoljno za njegovo zasićivanje arsenom, -
The pharmaceutical combination for use of any of the preceding claims, wherein in the patient to be treated, diabetes mellitus type 2 has been diagnosed at least 1 year or at least 2 years before onset of therapy. 
Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je kod pacijenta koji se treba liječiti, dijabetes melitus tipa 2 dijagnosticiran barem 1 godinu ili barem 2 godine prije početka liječenja.
airbag (possible locations depending of the type of seat) 
(97) Broj objave europskog patenta:
Freeze-dried melded article according to any one of the embodiments 1 to 16, which decomposes completely within ≦30seconds when liquid is added. 
Liofilizirani oblikovani proizvod sukladno zahtjevu 1 do 5, koji se potpuno raspada unutar < 30 sekundi od dodavanja tekućine.
GLA compounds of the present invention have the following formula (I): 
5 1. GLA spoj ima sljedeću strukturu (I):
The retentate fraction was collected and the ultrafilter washed with purified water. 
Zaostala frakcija sakupljena je, a ultrafilter je opran s pročišćenom vodom.
A compound of the formula R1 is selected from the group consisting of hydrogen, chloro, cyano, trifluoromethyl, difluoromethoxy, and trifluoromethoxy; 
Spoj formule [image] naznačen time što se bira iz skupine koju čine vodik, klor, cijano, trifluormetil, difluormetoksi, te trifluormetoksi;
A compound as claimed in any one of claims 1-12, or a pharmaceutically acceptable salt, or solvate thereof for use in the treatment of stroke, neuronal damage resulting from head trauma, epilepsy, seizures, neuronal loss following global and focal ischemia, pain, migraine, primary erythromelalgia, paroxysmal extreme pain disorder, cerebellar atrophy, ataxia, mental retardation, a neurodegenerative disorder, manic depression, tinnitus, myotonia, a movement disorder, or cardiac arrhythmia, or providing local anesthesia in a mammal, comprising administering an effective amount of said compound to a mammal in need of such treatment and wherein preferably said use is for treating pain and, wherein even more preferably said use is for preemptive or palliative treatment of pain; or ii) said pain is selected from the group consisting of chronic pain, inflammatory pain, neuropathic pain, acute pain, and surgical pain. 
Tvar u skladu s bilo kojim od patentnih zahtjeva 1-12, ili njena farmaceutski prihvatljiva sol ili solvat, za uporabu u liječenju moždanog udara, neurološkog oštećenja nastalog uslijed traume glave, epilepsije, konvulzija, gubitka neurona nakon globalne i fokalne ishemije, boli, migrene, primarne eritromelalgije, paroksizmalnog ekstremnog poremećaja boli, cerebelarne atrofije, ataksije, mentalne retardacije, neurodegenerativnog poremećaja, manične depresije, tinitusa, miotonije, poremećaja pokretanja, srčane aritmije, ili davanja lokalne anestezije sisavcima, obuhvaćajući primjenu učinkovite količine navedene tvari sisavcima koji imaju potrebu za takvim liječenjem 1 gdje je poželjna od navedenih uporaba tretiranje boli i gdje je još poželjnija i) - navedena uporaba prvotno ili palijativno liječenje boli; ili ii) navedena uporaba je odabrana 1z grupe koja se sastoji od kronične boli, upalne boli, neuropatske boli, akutne boli i kirurške boli.
The compound according to any of Claims 1 to 5, wherein the compound is a pharmaceutically acceptable salt of an anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfonate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, or citrate. 
Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je spoj farmaceutski prihvatljiva sol aniona kojeg se bira između klorida, bromida, jodida, sulfata, bisulfata, karbonata, bikarbonata, fosfata, hidrogensulfonata, p-toluensulfonata, metansulfonata, formijata, acetata, propionata, butirata, piruvata, laktata, oksalata, malonata, maleata, sukcinat, tartarata, fumarata, glikolata ili citrata.
grinding the mixture obtained in step iv), and 
V) mljevenje smjese dobivene u koraku iv), i vi) sabijanje smjese dobivene u koraku v).
A compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein R6 is C1-3 alkyl or C2-3 alkyl substituted by hydroxy. 
Spoj u skladu s patentnim zahtjevom 6 ili njegova farmaceutski prihvatljiva sol, naznačen time, da R* je Ci.3 alkil ili C,3 alkil supstituiran s hidroksi.
A process for manufacturing the compound of formula I-3 or a salt thereof, said process comprising: the reaction of the compound of formula I-1 wherein G1 represents halogen, or a salt of said compound, with 2-(tert -butoxy)ethanol in the presence of a base at a temperature from 25 to 140°C to obtain the compound of formula 1-2 as defined in claim 1, or a salt of said compound, and 
I-1 gdje G' predstavlja halogen, ili soli navedenog spoja, s 2-(tert-butoksijetanolom u prisutnosti lužine na temperaturi od 25 do 140*C, kako bi se dobio spoj formule I-2 kao što je definirano u zahtjevu 1, ili sol navedenog spoja, i reakcija spoja ili soli dobivenog/dobivene u koraku a) s TiCly u aprotonskom otapalu ili u smjesi otapala.
The method of item 2, wherein the weighting factors are associated with portions in a plurality of portions that include portions in autosomes or subset thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da su faktori ponderiranja povezani s dijelovima u većem broju dijelova koji uključuju dijelove u autosomima ili njihovim podskupinama,
In the present invention four intermediate values for the diameter φi, are preferably chosen, namely 25 mm, 38 mm, 50 mm and 76 mm. 
U ovom smo izumu po želji odabrali četiri prijelazne vrijednosti promjera Qi, tj. od 25, 38, 50 i 76 mm.
to 40 % by weight of disintegrant, and optionally 
D) 1 do 40 % masenog udjela razgrađujućeg sredstva, i izborno
The crude product was purified by flash chromatography on silica with gradient (heptane/ethyl acetate) elution. 
Sirovi produkt se pročišćava brzom kromatografijom na silika gelu uz korištenje gradijenta ispiranja (heptan/etil acetat).
a return water line from the industrial process to the container. 
liniju povratne vode (2) iz izmjenjivača topline (3) do spremnika;
from about 20 to about 700 µg of the compound from 1 to 2 times daily, or 
(li) od otprilike 20 do otprilike 700 ug tvari od 1 do 2 puta na dan, ili
The composition for the use of claim 13 or 14, wherein the factor Xa inhibitor is selected from the group consisting of fondaparinux, idraparinux, biotinylated idraparinux, enoxaparin, fragmin, NAP-5, rNAPc2, tissue factor pathway inhibitor, DX-9065a, YM-60828, YM-150, apixaban, rivaroxaban, PD-348292, otamixaban, DU-176b, LY517717, GSK913893, razaxaban, low molecular weight heparin, betrixaban or a pharmaceutically acceptable salt thereof, and combinations thereof. 
Pripravak za uporabu prema zahtjevu 10 ili 11, naznačen time da je inhibitor faktora Xa odabran iz skupine koju čine fondaparinuks, idraparinuks, biotinilirani idraparinuks, enoksaparin, fragmin, NAP-5, rNAPc2, inhibitor faktora tkivnog puta, DX-9065a, YM-60828, YM-150, apiksaban, rivaroksaban, PD-348292, otamiksaban, DU-176b, LY517717, GSK913893, razaksaban, heparin niske molekularne težine, betriksaban ili njihova farmaceutski prihvatljiva sol, te njihove kombinacije.
Nucleic acid according to item 1, wherein the nucleic acid does not contain one or two or at least one or all but one or all of the components of the group consisting of: a sequence encoding a ribozyme (preferably a self-splicing ribozyme), a viral nucleic acid sequence, a histon stem-loop processing signal, in particular a histon-stem loop processing sequence derived from mouse histon H2A614 gene, a Neo gene, an inactivated promoter sequence and an inactivated enhancer sequence. 
Nukleinska kiselina za uporabu prema zahtjevu 1 ili 2, naznačena time da nukleinska kiselina ne sadrži jednu ili dvije ili barem jednu ili sve osim jedne ili sve komponente skupine koja sadrži: sekvencu koja kodira ribozim ili samostalno-spajajući ribozim, sekvencu virusne nukleinske kiseline, signal za procesiranje histona peteljka-omča, naročito sekvencu za procesiranje signala histona peteljka-omča dobivenu iz mišjeg histon gena H2A614, Neo gen, inaktiviranu sekvencu promotora i inaktiviranu sekvencu pojačivača.